CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer
Gini, B., Gui, P., Wu, W., Wu, W., Kerr, D. L., Tan, L., Barbosa, D., Olivas, V., et al.
cancer biology
Quick verdict
Claims CDK4/6 upregulation drives EGFR-TKI resistance in EGFR-mutant lung cancer via replication stress and genomic instability; convincing model triangulation, though sequencing arms are underpowered.
Summary
This preclinical and translational study proposes a mechanism by which CDK4 or CDK6 amplification confers resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung adenocarcinoma. Overexpressing CDK4 or CDK6 in EGFR-mutant cell lines, a patient-derived organoid, and xenografts sustained DNA synthesis, Ki-67, and p-Rb during osimertinib treatment while raising replication stress markers (TPX2, p-RPA, p-ATM) and gamma-H2AX. Whole-exome sequencing of xenografts showed 15-20-fold higher fraction-of-genome-altered (FGA) without tumor mutation burden change. RNA/CNA integration identified amplified, overexpressed genes including AGR2, ASNS, STEAP1. In Foundation Medicine (n=660) and MSK-IMPACT GENIE (n=1983) cohorts, CDK4/6 CNAs associated with elevated FGA and whole-genome doubling; single-cell RNA-seq showed higher EMT scores in CDK4-amplified tumors. Osimertinib plus palbociclib or abemaciclib reversed these phenotypes. Limitations include small xenograft sequencing arms, overexpression-based mechanistic models, cohort-discordant CDK4 subgroup results, and no yet-reported clinical combination data.
Review complete
Assessment at a glance
6
risk flags identified
● high 2
● medium 3
● low 1
5 strengths · 5 weaknesses · 5 author questions
AI text signal = Binoculars zero-shot detector score over 20 sampled passages (Fast-DetectGPT co-reported) — absence does not prove human authorship, and a flag does not imply misconduct.
Levels reflect verification complexity — not a quality score. Evolve never rates your paper.
Key claims under review
- CDK4 or CDK6 overexpression sustains S-phase entry, p-Rb signaling, and proliferation during EGFR inhibition across engineered LUAD models including a patient-derived organoid, conferring osimertinib resistance.
- CDK4/6 upregulation induces replication stress and DNA damage (TPX2, p-RPA, p-ATM, gamma-H2AX) and increases the fraction of genome altered 15-20-fold without raising tumor mutation burden.
- CDK4/6 amplification in patient cohorts (Foundation Medicine n=660; MSK-IMPACT GENIE n=1983) is associated with significantly elevated FGA and WGD enrichment, with specificity over other cell-cycle alterations.
- CDK4 amplification correlates in patient cancer cells with upregulation of AGR2, ASNS, STEAP1, and CCZ1B and with higher EMT scores in single-cell RNA-seq.
- Co-treatment with osimertinib plus a CDK4/6 inhibitor (palbociclib or abemaciclib) restores proliferative arrest, induces apoptosis, and reduces replication stress, DNA damage, and FGA in preclinical models.
Strengths
Multi-model convergence on the resistance phenotype
CDK4/6 overexpression reduces osimertinib sensitivity across engineered H1975/PC9 CDXs, a TH107 patient-derived organoid (Supplementary Fig. 3), and is validated in the TH116 PDX from a patient who progressed on osimertinib and naturally harbors CDK6 amplification - a clinically grounded validation axis rather than engineered overexpression alone.
Large, orthogonal clinical corroboration with internal controls
Foundation Medicine (n=660) and MSK-IMPACT GENIE (n=1983) both show FGA elevation with CDK4/6 CNAs (Fig. 6A-D); specificity is addressed with negative controls (CCNE1, CDKN2A/B, CCND1/3, MDM2, NFKBIA show no FGA increase), a CDK4/6 copy-number dose-response (R2=0.286, p=0.003), WGD enrichment in TCGA, and TP53 balance between groups (68.3% vs 62.7%, p=0.13) excluding an obvious confounder.
Mechanistically coherent, literature-anchored cascade
Therapeutic reversal with two independent CDK4/6 inhibitors
Transparent methods including host-read contamination handling
Weaknesses
Severely underpowered sequencing arms
Causal language outruns the design
Metric semi-circularity for the genomic-instability claim
CDK4 patient-level support is inconsistent
Permissive statistical thresholds and small documentation slips
Full Review Report
$1.99 · one-timeUnlock the complete preliminary analysis Evolve produced for this paper.
Report preview
Preliminary Review: CDK4/6 Upregulation, Replication Stress, and EGFR-TKI Resistance
The remaining sections cover Methodology Assessment, Statistical Evidence, Results & Reproducibility, Limitations & Risks, and Verdict & Recommendations.
- All 5 strengths & 5 weaknesses, analyzed in detail
- 6 risk flags with severity, section & reviewer questions
- Methods & statistical evidence assessment
- 5 questions a peer reviewer would ask
- Full six-dimension evaluation report & recommendations
One-time purchase · this paper only
One-time purchase, this paper only. AI-generated preliminary analysis — not peer review.
Frequently asked questions
How does CDK4/6 amplification cause EGFR-targeted therapy resistance in lung cancer?
According to this preprint, CDK4/6 amplification keeps Rb phosphorylated so cells keep entering S-phase even when an EGFR inhibitor like osimertinib shuts off EGFR signaling. The forced proliferation causes DNA replication stress and damage (measured by TPX2, p-RPA, p-ATM, gamma-H2AX), activating resistance-promoting pathways and increasing copy-number instability: the fraction of the genome altered rose 15-20-fold in xenografts, with gains at pro-tumor loci such as AGR2, ASNS, and STEAP1.
Is there a treatment strategy proposed for CDK4/6-amplified EGFR-mutant lung cancer?
Yes - the paper combines osimertinib with CDK4/6 inhibitors (palbociclib or abemaciclib). In cell-line xenografts, a patient-derived organoid, and a CDK6-amplified patient-derived xenograft, the combination restored growth arrest, increased apoptosis, and reduced DNA damage and genomic instability. This provides a biomarker-driven rationale for an ongoing phase II trial of osimertinib plus abemaciclib, though results are not yet reported and the authors argue biomarker selection for CDK4/6 amplification will be needed.
What is the clinical evidence that CDK4/6 copy-number changes matter in EGFR-mutant lung cancer?
In two large cohorts (Foundation Medicine n=660 and MSK-IMPACT GENIE n=1983), EGFR-mutant tumors carrying CDK4 or CDK6 amplification had a significantly higher fraction of genome altered and were enriched for whole-genome doubling. CDK6 showed the association in both cohorts, while CDK4 was significant in only one (p=0.27 in Foundation Medicine). Tumor mutation burden did not rise, indicating a copy-number-driven instability pattern.
Can the computational results of this paper be reproduced?
Partially. Sequencing data are deposited (SRA PRJNA1093094; GEO GSE262270) and the analysis tools are standard (CNVkit, VarScan, GSEA, Scanpy), so the clinical-cohort FGA statistics and single-cell analyses could be re-derived from public data (MSK-IMPACT GENIE, TCGA, OncoSG). However, the Foundation Medicine data matrix is proprietary and no custom analysis code is shared, so full end-to-end reproduction is not possible.
About this review
This is an AI-generated preliminary review by Evolve.Pub, produced from the openly available text of the paper. It is not peer review and does not represent the authors' views. The canonical record of the paper is at the publisher link above.
- Main-text figures are only available as embedded text captions; plotted distributions, error bars, and per-group statistics could not be visually verified.
- Supplementary Figures 1-15 and Supplementary Tables 1-3 were not included in the extracted text, and several key results (organoid engineering, PDX validation, E2F1 knockdown) live there.
- Text extraction shows layout artifacts (line numbers, mixed header text); author lists differ slightly between the metadata block and the manuscript page, and copy-number values in figure text may be OCR-garbled.
- The full text may be truncated; some Methods passages appear compressed, so reporting judgments (e.g., absence of effect sizes) reflect what is visible in this extraction.
Go deeper on this paper
Wrote a paper? Stress-test it before reviewers do.
Upload your manuscript for the same structured scrutiny — reasoning, statistics, evidence, figures, and reproducibility.